Systemic corticosteroid monotherapy has no benefit for acute rhinosinusitis
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Roderick P. Venekamp and colleagues conducted a block-randomized, double-blind, placebo-controlled clinical trial at 54 primary care practices in the Netherlands over a span of 3 years.
Of the 174 patients included in the trial, those with facial pain or pressure on day 7 were 62.5% in the prednisone group and 55.8% in the placebo group. “The groups were similar with regard to the decrease over time in the proportion of patients with total symptoms and health-related quality of life,” the researchers wrote.
“Our study results indicate that the anti-inflammatory effect of corticosteroids seems to be of no benefit in the broad population of patients with clinically diagnosed acute rhinosinusitis,” the researchers added.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
